Findings

What do systematic reviews say?

7 questions · 7 findings · 1 reviews · Musculoskeletal

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 4 · 57.1%Moderate 1 · 14.3%High 2 · 28.6%

Anti‐TNF dose reduction vs anti‐TNF continuation

Disease activity · people with rheumatoid arthritis with low disease activity using a standard dose of anti‐TNF agents

1 finding from 1 review

Down‐titration and discontinuation strategies of tumour necrosis factor–blocking agents for rheumatoid arthritis in… 2019 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 501 participants
High

Anti‐TNF dose reduction vs anti‐TNF continuation

Maintenance of clinical remission · people with rheumatoid arthritis with low disease activity using a standard dose of anti‐TNF agents

Anti‐TNF dose reduction showed no clear difference in proportion of participants with persistent remission compared with anti‐TNF continuation (low certainty).

1 finding from 1 review

Down‐titration and discontinuation strategies of tumour necrosis factor–blocking agents for rheumatoid arthritis in… 2019 · Cochrane Headline outcomes only
RR 1.01 [0.8, 1.28]
2 studies · 612 participants
Low

Anti‐TNF dose reduction vs anti‐TNF continuation

Proportion of participants switched to another biologic · people with rheumatoid arthritis with low disease activity using a standard dose of anti‐TNF agents

Anti‐TNF dose reduction may leads to lower proportion of participants switched to another biologic compared with anti‐TNF continuation (low certainty).

1 finding from 1 review

Down‐titration and discontinuation strategies of tumour necrosis factor–blocking agents for rheumatoid arthritis in… 2019 · Cochrane Headline outcomes only
RR 0.4 [0.17, 0.93]
1 study · 323 participants
Low

Anti‐TNF dose reduction vs anti‐TNF continuation

Proportion of participants with minimal radiographic progression · people with rheumatoid arthritis with low disease activity using a standard dose of anti‐TNF agents

Anti‐TNF dose reduction showed no clear difference in proportion of participants with minimal radiographic progression compared with anti‐TNF continuation (moderate certainty).

1 finding from 1 review

Down‐titration and discontinuation strategies of tumour necrosis factor–blocking agents for rheumatoid arthritis in… 2019 · Cochrane Headline outcomes only
RR 1.22 [0.76, 1.95]
2 studies · 553 participants
Moderate

Anti‐TNF dose reduction vs anti‐TNF continuation

Function · people with rheumatoid arthritis with low disease activity using a standard dose of anti‐TNF agents

1 finding from 1 review

Down‐titration and discontinuation strategies of tumour necrosis factor–blocking agents for rheumatoid arthritis in… 2019 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 501 participants
High

Anti‐TNF dose reduction vs anti‐TNF continuation

Number of serious adverse events · people with rheumatoid arthritis with low disease activity using a standard dose of anti‐TNF agents

Anti‐TNF dose reduction showed no clear difference in number of serious adverse events compared with anti‐TNF continuation (low certainty).

1 finding from 1 review

Down‐titration and discontinuation strategies of tumour necrosis factor–blocking agents for rheumatoid arthritis in… 2019 · Cochrane Headline outcomes only
RR 1.09 [0.65, 1.82]
5 studies · 1084 participants
Low

Anti‐TNF dose reduction vs anti‐TNF continuation

Withdrawals due to adverse events · people with rheumatoid arthritis with low disease activity using a standard dose of anti‐TNF agents

Anti‐TNF dose reduction showed no clear difference in withdrawals due to adverse events compared with anti‐TNF continuation (low certainty).

1 finding from 1 review

Down‐titration and discontinuation strategies of tumour necrosis factor–blocking agents for rheumatoid arthritis in… 2019 · Cochrane Headline outcomes only
RR 1.07 [0.51, 2.24]
3 studies · 937 participants
Low